ClinicalTrials.Veeva

Menu

The Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block in Patients Undergoing Primary Total Hip Arthoplasty:

D

Diakonie-Klinikum Stuttgart

Status

Enrolling

Conditions

Randomized
Prospective
Double-blind

Treatments

Drug: Ropivacaine
Other: Physiological saline

Study type

Interventional

Funder types

Other

Identifiers

NCT06557044
Diak 001/2024

Details and patient eligibility

About

The aim of this study is to investigate the analgesic efficacy of the pericapsular nerve group (PENG) block during the implantation of hip endoprostheses. The study is designed as a prospective randomized double-blind study and the study participants were randomized into 2 arms and either 20 ml ropivacaine 0.5% (verum group) or 20 ml physiological saline solution (placebo group) will be applied.

Enrollment

110 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • planned cementless hip TEP operation for primary coxarthrosis via minimally invasive anterolateral approach using the identical implant system (Taperloc stem, Plamafit cup)
  • Patient capable of giving consent
  • Informed consent has been obtained
  • age > 18 years

Exclusion criteria

  • Refusal to participate in the study
  • Regular use of opioids
  • Known chronic pain symptoms
  • Infections in the area of the puncture site
  • Presence of a contraindication to ropivacaine
  • Presence of a contraindication to metamizole
  • Presence of a contraindication to postoperative analgesia with diclofenac
  • Secondary forms of osteoarthritis with deformities (i.e. high-grade dysplasia, secondary conditions after trauma, secondary conditions after childtrauma, secondary conditions after childhood hip joint diseases
  • Spinopelvic dysbalance, spinal canal stenosis
  • Previous operations on the hip/pelvis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

110 participants in 2 patient groups, including a placebo group

Verum Group
Experimental group
Description:
20 ml ropivacaine 0.5%
Treatment:
Drug: Ropivacaine
Placebo Group
Placebo Comparator group
Description:
20 ml physiological saline
Treatment:
Other: Physiological saline

Trial contacts and locations

1

Loading...

Central trial contact

Rainer Meierhenrich, Prof. Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems